Micregen welcomes Dr Athan Papadopoulos as new Managing Director

Micregen, a pioneering biotech company committed to increasing healthspan and prolonging the period of high-quality active life, is pleased to announce the appointment of Dr Athanasios Papadopoulos as Managing Director. Dr Papadopoulos, a consultant Bio-pathologist with over 20 years of global biopharmaceutical research, development and marketing authorisations’ experience, will take up his position on 1st October 2023.

Dr Papadopoulos brings a wealth of experience to Micregen, having spent many years in senior exec leadership roles within multinational biopharmaceutical companies like Novartis and Sanofi, guiding and managing multidisciplinary teams within the biopharmaceutical industry. His leadership acumen was evident in his previous role as Vice President and Chief Medical Officer at Emergex Vaccines Holding Ltd, where he contributed to pioneering a groundbreaking approach to immunotherapy and vaccine development, utilising cutting-edge technologies to create novel vaccines and immunopotentiation strategies.

Dr Papadopoulos held pivotal roles in the research, development, and global marketing authorisations of novel biologicals and medications bringing life-saving vaccines to the public, like the first vaccine approved to combat Dengue fever Dengvaxia®, the Fluad®, the Bexsero®, and others.

As Managing Director at Micregen, he will oversee strategic planning and day-to-day operations, working closely with Micregen's distinguished team of stem cell experts to drive the company's vision of increasing healthspan and prolonging the period of quality active life for everyone by leveraging innovative Secretomix® platform technology to tackle the root-causes of ageing, rather than merely treating the symptoms.

Barry Sharples, Executive Chairman and Co-founder at Micregen, expressed his thoughts on Dr Papadopoulos' appointment, stating; "The appointment of Athan as Managing Director marks a pivotal moment for Micregen as we continue to gain momentum, build shareholder value, and prepare for opening the next investment round. His exceptional accomplishments, dynamic leadership, and visionary outlook align with our innovative approach to tackling health and societal challenges. We extend our warmest welcome to him and offer our best wishes for success as we embark on an exciting new chapter.”